Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 454 / Drugs : 430 - (DrugBank : 90) / Drug target genes : 66 - Drug target pathways : 183

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

124I-AT-01
   Attralus, Inc.
      2021   Phase 2   NCT05235269   United States
   University of Tennessee Graduate School of Medicine
      2022   Phase 2   NCT05968846   United States
124I-AT03
   Attralus, Inc.
      2021   Phase 1   NCT05201911   United States
124I-labeled monoclonal antibody MU 11-1f4
   University of Tennessee
      2008   Phase 1   NCT01409148   United States
      2008   Phase 1   NCT00807872   United States
124I-P5+14 injection
   University of Tennessee Graduate School of Medicine
      2018   Phase 1/Phase 2   NCT03678259   United States
18F-fluoride PET
   University of Edinburgh
      2021   -   NCT05776212   Netherlands
2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
   John L. Berk
      2010   -   EUCTR2006-001066-16-GB   Italy;Sweden;United Kingdom
   John L. Berk, M.D.
      2007   -   EUCTR2006-001066-16-SE   Italy;Sweden;United Kingdom
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat
   FoldRx Pharmaceuticals, Inc.
      2007   Phase 2;Phase 3   EUCTR2006-002792-41-GB   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Ltd.
      2009   Phase 3   EUCTR2009-011535-12-FR   France;Germany;Italy;Portugal;Sweden
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate
   FoldRx Pharmaceuticals Limited
      2009   -   EUCTR2008-001262-87-DE   France;Germany;Portugal;Sweden
      2008   -   EUCTR2008-001262-87-SE   France;Germany;Portugal;Sweden
      2007   -   EUCTR2006-002792-41-DE   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-SE   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001262-87-PT   France;Germany;Portugal;Sweden
      2008   Phase 2;Phase 3   EUCTR2008-001262-87-FR   France;Germany;Portugal;Sweden
      2006   -   EUCTR2006-002792-41-PT   Germany;Portugal;Spain;Sweden;United Kingdom
3-(3-(3,5-dimethyl-1H-pyrazol-4-YL)propoxy)-4-fluorobenzoic acid
   Eidos Therapeutics, Inc
      2020   Phase 3   EUCTR2018-004670-10-IT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2019   Phase 3   EUCTR2018-004280-32-IT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Eidos Therapeutics, Inc.
      2022   Phase 3   EUCTR2020-005643-22-PT   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-NL   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-IE   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-GR   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-ES   Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-DK   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-CZ   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004670-10-PT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-HU   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-FR   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-DE   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-BG   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004280-32-PL   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-NL   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-GR   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-PT   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-IE   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-ES   Argentina;Australia;Belgium;Brazil;Canada;Denmark;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-DK   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-004670-10-NL   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey
4'-IODO-4'-deoxydoxorubicin
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00030381   United States
      1999   Phase 2   NCT00003853   Italy;United States
99MTC-PYP
   Mayo Clinic
      2023   Early Phase 1   NCT04899180   United States
   Shanghai General Hospital
      2025   -   ChiCTR2500112162   China
A01ac02
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
Aciclin
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Aciclovir
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Acoramidis
   Alexion Pharmaceuticals, Inc.
      2025   Phase 4   NCT07306949   Japan
   Bayer
      2026   Phase 4   NCT07298044   Austria;Belgium;Germany;Norway
      2025   -   NCT07235462   Germany
   Eidos Therapeutics, Inc
      2022   Phase 3   EUCTR2020-005643-22-IT   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
   Eidos Therapeutics, Inc.
      2022   Phase 3   EUCTR2020-005643-22-PT   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-NL   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-IE   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-GR   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-ES   Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-DK   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-CZ   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-PL   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-NL   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-PT   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-IE   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-DK   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
   Eidos Therapeutics, a BridgeBio company
      2025   Phase 3   NCT07116473   -
      2021   Phase 3   NCT04988386   Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;South Korea;Spain;United Kingdom;United States
      2021   Phase 3   NCT04882735   -
      2019   Phase 3   NCT03860935   Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
   Kitai Takeshi
      2026   -   JPRN-jRCT1051250227   -
   Minamisawa Masatoshi
      2025   Phase 4   JPRN-jRCT2071250063   -
Acyclovir
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
AG10
   Eidos Therapeutics
      2018   Phase 2   NCT03458130   United States
   Eidos Therapeutics, Inc.
      2022   Phase 3   EUCTR2020-005643-22-PT   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-NL   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-IE   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-GR   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-ES   Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-DK   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-CZ   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005643-22-BE   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-PL   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-NL   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-PT   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-IE   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-DK   Australia;Belgium;Brazil;Canada;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
   Eidos Therapeutics, a BridgeBio company
      2025   Phase 3   NCT07116473   -
      2021   Phase 3   NCT04988386   Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;South Korea;Spain;United Kingdom;United States
      2020   Phase 3   NCT04418024   Canada;Spain;United States
AG10 HCI
   Eidos Therapeutics, Inc
      2019   Phase 3   EUCTR2018-004280-32-IT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
AG10 HCL
   Eidos Therapeutics, Inc
      2022   Phase 3   EUCTR2020-005643-22-IT   Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Greece;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004670-10-IT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2019   Phase 3   EUCTR2018-004280-32-IT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Eidos Therapeutics, Inc.
      2020   Phase 3   EUCTR2018-004670-10-PT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-HU   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-FR   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-DE   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-BG   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004280-32-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004280-32-GR   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004280-32-ES   Argentina;Australia;Belgium;Brazil;Canada;Denmark;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2018-004670-10-NL   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey
Akcea-TTR-LRX
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-002835-27-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Japan;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002835-27-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Israel;Italy;Japan;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Alkeran
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
   European Myeloma Network
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
Allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
ALN-51547
   ALNYLAM PHARMACEUTICALS, INC.
      2015   Phase 3   EUCTR2014-003835-20-IT   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-005333-49-GB   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-SE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-ES   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-DE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-BE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-003835-20-GB   Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
ALN-65492
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
ALN-TTR02
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
ALN-ttrsc
   ALNYLAM PHARMACEUTICALS, INC.
      2015   Phase 3   EUCTR2014-003835-20-IT   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-005333-49-GB   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-SE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-ES   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-DE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-BE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-003835-20-GB   Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
ALN-ttrsc02
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224769   Asia except Japan;Europe;Japan;North America;Oceania;South America
ALXN2060
   Alexion Pharmaceuticals, Inc.
      2020   Phase 3   NCT04622046   Japan
ALXN2220
   Alexion Pharmaceuticals, Inc.
      2024   Phase 3   NCT06183931   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;South Korea;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
   AstraZeneca
      2026   Phase 2   NCT07608354   Canada;China;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom;United States
   Neurimmune AG
      2025   Phase 2   NCT07213583   France;Germany;Netherlands;Spain
Amifostine trihydrate
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
Anakinra
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2006-001927-20-IT   Italy
Anselamimab
   Stanford University
      2026   Early Phase 1   NCT07615270   United States
ANTI-CD38 monoclonal antibody
   University of Turin, Italy
      2022   -   NCT06571864   Italy
Antistaminico
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
Antiviral therapy
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Aprotinin
   National Center for Global Health and Medicine
      2010   -   JPRN-UMIN000012319   Japan
AT-02
   Attralus, Inc.
      2022   Phase 1   NCT05521022   Australia;United States
AT02
   Attralus, Inc.
      2023   Phase 2   NCT05951049   Australia;United Kingdom;United States
ATTR-CM
   Fujimoto Naoki
      2020   Phase 4   JPRN-jRCT1041200007   -
   Kitai Takeshi
      2026   -   JPRN-jRCT1051250227   -
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2021   Phase 4   NCT04935021   China
   Shanghai General Hospital
      2025   -   ChiCTR2500112162   China
Autologous bone marrow transplantation
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
Autologous hematopoietic stem cell transplantation
   Mayo Clinic
      2005   Phase 3   NCT00477971   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Autologous peripheral blood stem cell transplantation
   Boston Medical Center
      2000   Phase 2   NCT00075621   United States
Autologous stem cell transplant
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Autologous stem cell transplantation
   Boston Medical Center
      2001   Phase 2   NCT00075608   United States
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
   University Hospital, Limoges
      2000   Phase 3   NCT00344526   France
Autologous-autologous tandem hematopoietic stem cell transplantation
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
AZD0120
   Alexion Pharmaceuticals, Inc.
      2025   Phase 1/Phase 2   NCT07081646   Canada;United Kingdom;United States
Bassado - 100 MG compresse 10 compresse
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2018   Phase 2   EUCTR2017-002210-31-IT   Germany;Italy
Bcma bispecific
   Case Comprehensive Cancer Center
      2026   Phase 2   NCT07524634   United States
Belantamab mafodotin
   European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-NL   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-GR   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-FR   France;Germany;Greece;Italy;Netherlands;United Kingdom
   GlaxoSmithKline
      2026   Phase 2   NCT07224672   -
   STICHTING EUROPEAN MYELOMA NETWORK
      2021   Phase 2   EUCTR2020-004001-32-IT   France;Germany;Greece;Italy;Netherlands;United Kingdom
   Stichting European Myeloma Network
      2021   Phase 2   NCT04617925   France;Germany;Greece;Italy;Netherlands;United Kingdom
   Stichting European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-DE   France;Germany;Greece;Italy;Netherlands;United Kingdom
Belantamab mafodotin every 8 weeks or 12 weeks AS determined BY part 1 recommended dosages
   University of Texas Southwestern Medical Center
      2024   Phase 1/Phase 2   NCT05145816   United States
Bendamustine
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
      2013   Phase 2   NCT01222260   United States
Betamethasone
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Biopsy
   National Center for Global Health and Medicine
      2010   -   JPRN-UMIN000012319   Japan
Biospecimen collection
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Birtamimab
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Prothena Biosciences Limited
      2023   Phase 3   EUCTR2021-000037-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PT   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-HU   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-GR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-ES   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
   Prothena Biosciences Ltd.
      2021   Phase 3   NCT04973137   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;South Korea;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Blood collection
   Boston Medical Center
      2016   -   NCT02716103   United States
Blood samples FOR ANTI-drug antibodies
   Akcea Therapeutics
      2021   Phase 4   NCT04306510   Canada;United States
Blood samples FOR immunoglobulins
   Akcea Therapeutics
      2021   Phase 4   NCT04306510   Canada;United States
Blood samples FOR inflammatory markers
   Akcea Therapeutics
      2021   Phase 4   NCT04306510   Canada;United States
Bmdex
   European Myeloma Network
      2011   Phase 3   NCT01277016   Italy
Bone marrow ablation with stem cell support
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
Bone marrow aspiration
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Bone marrow aspiration and biopsy
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Bone marrow biopsy
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Bone marrow collection
   Boston Medical Center
      2016   -   NCT02716103   United States
Bortezomib
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Barbara Ann Karmanos Cancer Institute
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
      2007   Phase 2   NCT00520767   United States
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
      2009   Phase 2   NCT01083316   United States
      2008   Phase 2   NCT00790647   United States
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   Emory University
      2021   Phase 1   NCT04754945   United States
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GlaxoSmithKline
      2026   Phase 2   NCT07224672   -
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
      2012   Phase 2   EUCTR2010-021445-42-BE   Belgium;Germany;Netherlands
      2011   Phase 2   EUCTR2010-021445-42-NL   Belgium;Germany;Netherlands
   JANSSEN-CILAG
      2005   -   EUCTR2004-004871-12-IT   Italy
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Poland;Romania;South Korea;Spain;Sweden;Turkey (Türkiye);United Kingdom;United States
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
   Jin Lu, MD
      2024   Phase 2   NCT06342466   China
      2024   -   NCT06192979   China
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
      2010   Phase 2   NCT01072773   United States
   Memorial Sloan Kettering Cancer Center
      2007   Phase 2   NCT00458822   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   National Cancer Institute (NCI)
      2010   Phase 3   NCT01078454   United States
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Peking University People's Hospital
      2024   -   NCT06627309   China
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   University College London
      2010   -   EUCTR2009-014906-33-GB   United Kingdom
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
   Zhi-Hong Liu, M.D.
      2011   -   NCT01273844   China
Bortezomib accord
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Bortezomib D-mannitol
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Bortezomib/dexamethasone (BD), followed BY autologous STC & maintenance bortezomib/dexamethasone
   Memorial Sloan Kettering Cancer Center
      2011   -   NCT01383759   United States
Busulfan
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
CAEL-101
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2019-004254-28-IT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-000713-32-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-000713-32-CZ   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-000713-32-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-004254-28-NL   Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-004254-28-CZ   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-004254-28-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-PL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-PL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04512235   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russia;South Korea;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04504825   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russia;South Korea;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   NCT04304144   United States
      2020   Phase 3   EUCTR2020-000713-32-GR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000713-32-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-GR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Caelum Biosciences, Inc.
      2021   Phase 3   EUCTR2020-000713-32-IT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-GB   Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
Carboplatin
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
Carfilzomib
   University College, London
      2015   Phase 1/Phase 2   NCT02545907   United Kingdom
Carmustine
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
CC-4047
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   OSPEDALE POLICLINICO S. MATTEO
      2012   -   EUCTR2011-001787-22-IT   Italy
CC-5013
   Mayo Clinic
      2005   Phase 2   NCT00166413   United States
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
Cetirizina dicloridrato
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Chemotherapy
   IRCCS Policlinico S. Matteo
      2015   Phase 2   NCT01531751   Italy
Chimeric fibril-reactive IGG1K monoclonal antibody 11-1f4
   Caelum Biosciences, Inc.
      2021   Phase 3   EUCTR2020-000713-32-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-GB   Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
Chimeric fibril-reactive monoclonal ANTI-body 11-1f4
   Alexion Pharmaceuticals, Inc.
      2014   Phase 1   NCT02245867   United States
CHX A-dtpa ANTI-CD66 antibody
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
CHX-A-DTPA-ANTI-CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Ciltacabtagene autoleucel
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Cisplatin
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
CM-336 bcma/CD3 bispecific antibody
   Institute of Hematology & Blood Diseases Hospital, China
      2025   -   NCT06769555   -
Computed tomography
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Coramitug
   Novo Nordisk A/S
      2026   Phase 1   NCT07448623   Netherlands
Current treatment OF AL-CM
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2021   -   NCT04924998   China
Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence IN situ hybridization (fish) assay
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
Cyclophosphamide
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
   Emory University
      2021   Phase 1   NCT04754945   United States
   GlaxoSmithKline
      2026   Phase 2   NCT07224672   -
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   Guangdong Provincial People's Hospital
      2020   Phase 4   NCT04612582   China
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   IRCCS Policlinico S. Matteo
      2008   Phase 2   NCT00607581   Italy
   Icahn School of Medicine at Mount Sinai
      2017   Phase 1/Phase 2   NCT03236792   United States
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Poland;Romania;South Korea;Spain;Sweden;Turkey (Türkiye);United Kingdom;United States
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
   Mayo Clinic
      2010   Phase 2   NCT01072773   United States
      2007   Phase 2   NCT00564889   United States
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
   PETHEMA Foundation
      2010   Phase 2   NCT01194791   Spain
   Peking University People's Hospital
      2024   -   NCT06627309   China
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Cyclophosphamide, bortezomib, and dexamethasone (cybord) regimen
   Alexion Pharmaceuticals, Inc.
      2020   Phase 3   NCT04512235   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russia;South Korea;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04504825   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russia;South Korea;Spain;Switzerland;United Kingdom;United States
Cyclosporine
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
Dapagliflozin
   Barbara Ann Karmanos Cancer Institute
      2024   Phase 2   NCT06420167   United States
Dara IV
   Peking University People's Hospital
      2024   -   NCT06627309   China
Dara SC
   Peking University People's Hospital
      2024   -   NCT06627309   China
Daratumumab
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
   Boston Medical Center
      2017   Phase 1/Phase 2   NCT02841033   United States
   CHU DE LIMOGES
      2017   Phase 2   EUCTR2016-000287-42-IT   France;Italy
   CHU de Limoges
      2016   Phase 2   EUCTR2016-000287-42-FR   France
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2021   Phase 2   EUCTR2019-001962-13-IT   Italy
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-IT   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Poland;Romania;South Korea;Spain;Sweden;Turkey (Türkiye);United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
   Jin Lu, MD
      2024   -   NCT06192979   China
   M.D. Anderson Cancer Center
      2018   Phase 1   NCT03283917   United States
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   Peking University People's Hospital
      2026   Phase 2   NCT07335887   -
   University Hospital, Limoges
      2016   Phase 2   NCT02816476   France;Italy
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
Daratumumab and hyaluronidase-fihj
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Suzanne Lentzsch, MD
      2025   Phase 2   NCT07110844   United States
Daratumumab and pomalidomide
   Fondazione IRCCS Policlinico San Matteo di Pavia
      2021   Phase 2   NCT04895917   Italy
Daratumumab injection
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Daratumumab SC
   Weill Medical College of Cornell University
      2021   Phase 2   NCT04270175   United States
Daratumumab/daratumumab and hyaluronidase-fihj
   Yongyong MA
      2024   -   NCT06455748   China
Darzalex
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Dazarlex
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
Deaxamethasone
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
Decadron
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
Desametasone
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Desametasone sodio fosfato
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Dexametasone
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Dexamethason
   European Myeloma Network
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
Dexamethasone
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
      2007   Phase 2   NCT00520767   United States
   Boston Medical Center
      2012   Phase 1/Phase 2   NCT01570387   United States
      2009   Phase 2   NCT01083316   United States
      2008   Phase 2   NCT00679367   United States
   Columbia University
      2013   Phase 2   NCT01222260   United States
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022395-31-SE   Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   Emory University
      2021   Phase 1   NCT04754945   United States
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   GlaxoSmithKline
      2026   Phase 2   NCT07224672   -
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   IRCCS Policlinico S. Matteo
      2008   Phase 2   NCT00607581   Italy
   Icahn School of Medicine at Mount Sinai
      2017   Phase 1/Phase 2   NCT03236792   United States
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
   Jin Lu, MD
      2024   Phase 2   NCT06342466   China
      2024   -   NCT06192979   China
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
   M.D. Anderson Cancer Center
      2018   Phase 1   NCT03283917   United States
      2014   Phase 1   NCT01807286   United States
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
      2010   Phase 2   NCT01072773   United States
      2007   Phase 2   NCT00564889   United States
      2005   Phase 3   NCT00477971   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03618537   United States
      2007   Phase 2   NCT00458822   United States
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
      2010   Phase 3   NCT01078454   United States
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
   Oncopeptides AB
      2020   Phase 1/Phase 2   NCT04115956   Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   PETHEMA Foundation
      2010   Phase 2   NCT01194791   Spain
   Peking University People's Hospital
      2026   Phase 2   NCT07335887   -
      2024   -   NCT06627309   China
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
      1996   Phase 2   NCT00002849   United States
   Stanford University
      2009   -   NCT00890552   United States
   Tufts Medical Center
      2017   Phase 1   NCT03000660   United States
   University College, London
      2015   Phase 1/Phase 2   NCT02545907   United Kingdom
   University Hospital, Limoges
      2000   Phase 3   NCT00344526   France
   Vaishali Sanchorawala
      2004   Phase 2   NCT00091260   United States
   Weill Medical College of Cornell University
      2021   Early Phase 1   NCT04984330   United States
      2021   Phase 2   NCT04270175   United States
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
   Yongyong MA
      2024   -   NCT06455748   China
Dexamethasone 4 MG jenapharm
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Dexamethasone krka
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Dexamethasone oral, 10 MG
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Dexamethasone oral, 20 MG
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Dexamethasone sodium sulfate
   OSPEDALE POLICLINICO S. MATTEO
      2012   -   EUCTR2011-001787-22-IT   Italy
Dexamethasone, 40 MG
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Poland;Romania;South Korea;Spain;Sweden;Turkey (Türkiye);United Kingdom;United States
Dexaton
   European Myeloma Network
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
Dezamizumab
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Diflunisal
   Boston University
      2006   Phase 2/Phase 3   NCT00294671   Italy;Japan;Portugal;Sweden;United Kingdom;United States
   Department of Neurology, Faculty of Life Sciences, Kumamoto University
      2012   Phase 3   JPRN-UMIN000008396   Japan
   John L. Berk
      2010   -   EUCTR2006-001066-16-GB   Italy;Sweden;United Kingdom
   John L. Berk, M.D.
      2007   -   EUCTR2006-001066-16-SE   Italy;Sweden;United Kingdom
   Shinshu University
      2009   -   JPRN-UMIN000001825   Japan
Diuretics (plus antiarrhythmic drugs, I.E. amiodarone, IN case OF complex ventricular arrhythmias) plus egcg
   IRCCS Policlinico S. Matteo
      2012   Phase 2   NCT01511263   Italy
DNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Dobutamine stress echocardiography
   Steen Hvitfeldt Poulsen
      2024   -   NCT06372301   Denmark
Dobutrex
   Steen Hvitfeldt Poulsen
      2024   Phase 1/Phase 2   NCT06318260   Denmark
Dolobid
   Boston University- The Amyloid Treatment and Research Program
      2007   -   EUCTR2006-001066-16-IT   Italy;Sweden;United Kingdom
   John L. Berk
      2010   -   EUCTR2006-001066-16-GB   Italy;Sweden;United Kingdom
   John L. Berk, M.D.
      2007   -   EUCTR2006-001066-16-SE   Italy;Sweden;United Kingdom
Donor lymphocytes
   Fred Hutchinson Cancer Research Center
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
Doxiciclina
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2018   Phase 2   EUCTR2017-002210-31-IT   Germany;Italy
Doxorubicin
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Doxycycline
   Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
      2019   Phase 2;Phase 3   EUCTR2017-002210-31-DE   Canada;Germany;Italy;Turkey
   Fondazione IRCCS Policlinico San Matteo di Pavia
      2019   Phase 2/Phase 3   NCT03474458   Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom
   Medical College of Wisconsin
      2014   Phase 2   NCT02207556   United States
Doxyhexal® tabs 100 MG tabletten
   Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
      2019   Phase 2;Phase 3   EUCTR2017-002210-31-DE   Canada;Germany;Italy;Turkey
Echocardiography
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Echocardiography test
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Elotuzumab
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
Elranatamab
   Brigham and Women's Hospital
      2024   Phase 1/Phase 2   NCT06569147   United States
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Empagliflozin
   Columbia University
      2022   Phase 4   NCT05233163   United States
Enbrel
   The Cleveland Clinic
      2001   Phase 2   NCT00224393   -
Endoxan
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Epigallocatechin
   Florian Michel
      2013   Phase 2   NCT02015312   Germany
Eplontersen
   AstraZeneca
      2026   Phase 2   NCT07608354   Canada;China;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   NCT06194825   China
   Brice Gary
      2025   Phase 3   JPRN-jRCT2071250030   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-001427-40-IT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
   Ionis Pharmaceuticals, Inc.
      2022   Phase 3   NCT05667493   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001427-40-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-FR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-ES   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-CY   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2021   Phase 3   EUCTR2019-002835-27-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   NCT04136171   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Puerto Rico;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
EQUE-CEL CAR-T therapy
   Nanjing IASO Biotechnology Co., Ltd.
      2025   Phase 2   NCT07055724   -
Etentamig
   AbbVie
      2024   Phase 1/Phase 2   NCT06158854   Australia;France;Greece;Italy;Japan;United States
   Satomi Natsuko
      2024   Phase 1-2   JPRN-jRCT2071230131   Australia;France;Greece;Italy;Japan;United States of America
Etoposide
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Filgrastim
   Boston Medical Center
      2008   Phase 2   NCT00790647   United States
      2001   Phase 2   NCT00075608   United States
      2000   Phase 2   NCT00075621   United States
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Mayo Clinic
      2005   Phase 3   NCT00477971   United States
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
Fish assay
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Flow cytometry
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Fludarabine phosphate
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
Fortecortin
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
   European Myeloma Network
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
Foscarnet sodium
   City of Hope Medical Center
      2010   -   NCT01199562   United States
FX-1006A
   FOLDRX PHARMACEUTICALS, INC.
      2010   Phase 3   EUCTR2009-011535-12-IT   France;Germany;Italy;Portugal;Sweden
      2008   -   EUCTR2007-006791-12-IT   France;Germany;Italy
   FoldRx Pharmaceuticals Limited
      2009   -   EUCTR2008-001262-87-DE   France;Germany;Portugal;Sweden
      2008   -   EUCTR2008-001262-87-SE   France;Germany;Portugal;Sweden
      2007   -   EUCTR2006-002792-41-DE   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-SE   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001262-87-PT   France;Germany;Portugal;Sweden
      2008   Phase 2;Phase 3   EUCTR2008-001262-87-FR   France;Germany;Portugal;Sweden
      2007   Phase 2;Phase 3   EUCTR2006-002792-41-GB   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-PT   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Ltd.
      2009   Phase 3   EUCTR2009-011535-12-FR   France;Germany;Italy;Portugal;Sweden
   Pfizer
      2008   Phase 2/Phase 3   NCT00791492   Argentina;Brazil;France;Germany;Portugal;Sweden
      2007   Phase 2/Phase 3   NCT00409175   Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States
   Pfizer Inc.
      2009   -   EUCTR2009-011535-12-PT   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
      2009   -   EUCTR2009-011535-12-DE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Ganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States
GC012F injection
   Gracell Biotechnologies (Shanghai) Co., Ltd.
      2025   Phase 1   NCT07250269   China
GLA gene
   Shanghai General Hospital
      2025   -   ChiCTR2500112162   China
Granulocyte colony stimulating factor
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
GSK2315698
   GlaxoSmithKline
      2018   Phase 1   NCT03417830   Sweden
      2013   Phase 1   NCT01777243   United Kingdom
      2011   Phase 1   NCT01406314   United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
GSK2398852
   GlaxoSmithKline
      2018   Phase 1   NCT03417830   Sweden
      2013   Phase 1   NCT01777243   United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
GSK2857916
   European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-NL   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-GR   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-FR   France;Germany;Greece;Italy;Netherlands;United Kingdom
   STICHTING EUROPEAN MYELOMA NETWORK
      2021   Phase 2   EUCTR2020-004001-32-IT   France;Germany;Greece;Italy;Netherlands;United Kingdom
   Stichting European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-DE   France;Germany;Greece;Italy;Netherlands;United Kingdom
GSK3039294
   GlaxoSmithKline
      2016   Phase 1   NCT02603172   United Kingdom
H02ab02
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
H02ab02 desametasone
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
High CUT-OFF hemodialysis
   IRCCS Policlinico S. Matteo
      2015   Phase 2   NCT01531751   Italy
Human transthyretin antisense oligonucleotide
   Ionis Pharmaceuticals, Inc
      2015   Phase 3   EUCTR2013-004561-13-GB   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2013-004561-13-DE   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-005115-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005115-13-ES   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-PT   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-GB   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-DE   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-GB   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-FR   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc
      2015   -   EUCTR2013-004561-13-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-FR   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc.
      2015   -   EUCTR2012-001831-30-BG   Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States
      2014   Phase 2;Phase 3   EUCTR2012-001831-30-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-IT   Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
Humanised IGG1 monoclonal antibody against misfolded transthyretin
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
   Novo Nordisk A/S
      2023   Phase 2   EUCTR2021-006226-49-PT   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006226-49-NL   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006226-49-DE   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006226-49-CZ   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
Humanized IGG1 kappa antiamyloid
   Prothena Biosciences Limited
      2023   Phase 3   EUCTR2021-000037-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PT   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-HU   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-GR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-ES   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
Humanized IGG1, kappa ANTI-serum amyloid A and ANTI-AL amyloid antibody
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2017   Phase 2   EUCTR2016-000489-50-IT   Italy
   Prothena Therapeutics Limited
      2018   Phase 2   EUCTR2016-004664-18-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GR   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-ES   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-ES   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
Humax-CD38
   CHU DE LIMOGES
      2017   Phase 2   EUCTR2016-000287-42-IT   France;Italy
   CHU de Limoges
      2016   Phase 2   EUCTR2016-000287-42-FR   France
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   JANSSEN CILAG INTERNATIONAL NV
      2018   Phase 3   EUCTR2016-001737-27-IT   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
Humax-CD38, 3003-005
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
Hyaluronidase
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
Ibrutinib
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
Idecabtagene vicleucel
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Imatinib mesylate
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00025415   United States
Imnovid
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2021   Phase 2   EUCTR2019-001962-13-IT   Italy
Imnovid 1 MG
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Imnovid 2 MG
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Imnovid 4 MG
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Indium 111-radiolabelled ANTI-CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Indium 111 labelled anti-CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Infection prophylaxis and management
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Inoserten
   Ionis Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
Inotersen
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001698-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-CY   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2018   -   NCT03400098   United States
      2018   Phase 3   EUCTR2017-005115-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   NCT02175004   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2/Phase 3   NCT01737398   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-GB   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-FR   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
Iodine
   University of Tennessee Graduate School of Medicine
      2022   Phase 2   NCT05968846   United States
ION-682884
   Brice Gary
      2025   Phase 3   JPRN-jRCT2071250030   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-001427-40-IT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2020   Phase 3   EUCTR2019-002835-27-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-001427-40-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-FR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-ES   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-CY   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2021   Phase 3   EUCTR2019-002835-27-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Japan;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-002835-27-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-001698-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-002835-27-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Israel;Italy;Japan;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002835-27-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-CY   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
ION-682884product code: ION-682884pharmaceutical form: solution FOR injectioninn or proposed INN: eplontersencas number: 1637600-16-8current sponsor code: ION-682884other descriptive name: akcea-TTR-lrxconcentration unit: MG/ML milligram(S)/millilitreconcentration type: equalconcentration number: 150-pharmaceutical form OF THE placebo: solution FOR injectionroute OF administration OF THE placebo: subcutaneous USE
   Ionis Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-002835-27-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Isatuximab
   Emory University
      2021   Phase 1   NCT04754945   United States
   Intergroupe Francophone du Myelome
      2022   Phase 2   NCT05066607   France
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
   SWOG Cancer Research Network
      2018   Phase 2   NCT03499808   United States
Isis 420915
   Ionis Pharmaceuticals, Inc
      2015   Phase 3   EUCTR2013-004561-13-GB   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2013-004561-13-DE   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001698-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-CY   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2018   Phase 3   EUCTR2017-005115-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005115-13-ES   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-PT   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-GB   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-DE   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-GB   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-FR   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc
      2015   -   EUCTR2013-004561-13-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-FR   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc.
      2015   -   EUCTR2012-001831-30-BG   Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States
      2014   Phase 2;Phase 3   EUCTR2012-001831-30-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-IT   Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
Isis 420915/GSK 299872
   Brigham and Women's Hospital
      2016   Phase 2   NCT02627820   -
Ixazomib
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
   Icahn School of Medicine at Mount Sinai
      2017   Phase 1/Phase 2   NCT03236792   United States
   M.D. Anderson Cancer Center
      2018   Phase 1   NCT03283917   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03618537   United States
Ixazomib citrate
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
JNJ 54767414
   JANSSEN CILAG INTERNATIONAL NV
      2018   Phase 3   EUCTR2016-001737-27-IT   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
JNJ-54767414
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
JNJ-79635322
   Janssen Research & Development, LLC
      2022   Phase 1   NCT05652335   Belgium;France;Japan;Netherlands;Spain;United Kingdom;United States
Kineret*SC 7SIR 100MG 0,67ML
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2006-001927-20-IT   Italy
KP-2541
   K-Group Alpha, Inc
      2023   Phase 1;Phase 2   EUCTR2021-003008-42-CY   Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;United Kingdom;United States
   K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
      2021   Phase 1;Phase 2   EUCTR2021-003008-42-GR   Australia;Cyprus;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;United States
L01aa03
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
Laboratory biomarker analysis
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
      2007   Phase 2   NCT00520767   United States
   City of Hope Medical Center
      2010   -   NCT01199562   United States
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
   National Cancer Institute (NCI)
      2009   Phase 1   NCT00890747   United States
   SWOG Cancer Research Network
      2018   Phase 2   NCT03499808   United States
Lenalidomide
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
   Boston Medical Center
      2008   Phase 2   NCT00679367   United States
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Heidelberg University
      2009   Phase 2   NCT00883623   Germany
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   IRCCS Policlinico S. Matteo
      2008   Phase 2   NCT00607581   Italy
   Mayo Clinic
      2007   Phase 2   NCT00564889   United States
   PETHEMA Foundation
      2010   Phase 2   NCT01194791   Spain
   Stanford University
      2009   -   NCT00890552   United States
   Vaishali Sanchorawala
      2004   Phase 2   NCT00091260   United States
Lenalidomide 25MG
   Seoul National University Hospital
      2019   Phase 3   NCT04298372   Korea, Republic of
Lenalidomide, dexamethasone and cyclophosphamide
   University of Athens
      2008   Phase 1/Phase 2   NCT00981708   Greece
Lenogastrim
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
Leukine
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Linvoseltamab
   Regeneron Pharmaceuticals
      2024   Phase 1/Phase 2   NCT06292780   Greece;South Korea;Spain;United Kingdom;United States
Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with bortezomib+dexamethasone/bortezomib+dexamethasone+daratumumab/single daratumumab
   Air Force Military Medical University, China
      2023   Phase 3   NCT05776940   -
Magnetic resonance imaging
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Management OF therapy complications
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Melflufen
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1/Phase 2   NCT04115956   Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Melphalan
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
      2009   Phase 2   NCT01083316   United States
      2008   Phase 2   NCT00790647   United States
      2008   Phase 2   NCT00679367   United States
      2001   Phase 2   NCT00075608   United States
      2000   Phase 2   NCT00075621   United States
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022395-31-SE   Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   European Myeloma Network
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
   M.D. Anderson Cancer Center
      2014   Phase 1   NCT01807286   United States
   Mayo Clinic
      2005   Phase 3   NCT00477971   United States
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   National Cancer Institute (NCI)
      2010   Phase 3   NCT01078454   United States
   Oncopeptides AB
      2020   Phase 1/Phase 2   NCT04115956   Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
   Stanford University
      2009   -   NCT00890552   United States
   University Hospital, Limoges
      2000   Phase 3   NCT00344526   France
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Melphalan fulfenamide hydrochloride
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Melphalan, thalidomide and dexamethasone
   FDA Office of Orphan Products Development
      2002   Phase 2   NCT01527032   -
Microarray analysis
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
Miridesap
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Multivitaminico adulti teva
   IONIS PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-002835-27-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Japan;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Mycophenolate mofetil
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium
   FoldRx Pharmaceuticals Limited
      2009   -   EUCTR2008-001262-87-DE   France;Germany;Portugal;Sweden
      2008   -   EUCTR2008-001262-87-SE   France;Germany;Portugal;Sweden
      2007   -   EUCTR2006-002792-41-DE   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-SE   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001262-87-PT   France;Germany;Portugal;Sweden
      2008   Phase 2;Phase 3   EUCTR2008-001262-87-FR   France;Germany;Portugal;Sweden
      2007   Phase 2;Phase 3   EUCTR2006-002792-41-GB   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-PT   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Ltd.
      2009   Phase 3   EUCTR2009-011535-12-FR   France;Germany;Italy;Portugal;Sweden
NEOD001
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2017   Phase 2   EUCTR2016-000489-50-IT   Italy
   Prothena Therapeutics Limited
      2018   Phase 2   EUCTR2016-004664-18-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GR   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-ES   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-ES   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
   Prothena Therapeutics Ltd.
      2017   Phase 2   NCT03154047   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   NCT02632786   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   NCT02613182   United States
      2015   Phase 3   NCT02312206   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Neupogen
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
Nexiguran ziclumeran
   Intellia Therapeutics
      2024   Phase 3   NCT06672237   Argentina;Australia;Brazil;Mexico;New Zealand;Singapore;Taiwan;Thailand
NNC6019-0001
   Brian Malling
      2025   Phase 3   JPRN-jRCT2071250120   Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Italy;Japan;Netherlands;South Korea;Spain;United Kingdom;United States
   Ito Junji
      2024   Phase 2   JPRN-jRCT2071240078   Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United states
      2023   Phase 2   JPRN-jRCT2061230027   Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United states
   Novo Nordisk A/S
      2025   Phase 3   NCT07207811   Argentina;Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;South Korea;Spain;Sweden;United Kingdom;United States
      2024   Phase 2   NCT06260709   Canada;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United States
      2022   Phase 2   NCT05442047   Canada;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United States
NNC6019-0001 A 250 MG
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
   Novo Nordisk A/S
      2023   Phase 2   EUCTR2021-006226-49-PT   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006226-49-NL   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006226-49-DE   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-006226-49-CZ   Canada;Czech Republic;European Union;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
NTLA-2001
   Intellia Therapeutics
      2023   Phase 3   NCT06128629   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Portugal;Singapore;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States
      2020   Phase 1   NCT04601051   France;New Zealand;Sweden;United Kingdom
   Olbertz Joy
      2025   Phase 3   JPRN-jRCT2053250023   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Singapore;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States
Nucresiran
   Alnylam Pharmaceuticals
      2025   Phase 3   NCT07223203   Australia;Brazil;Cyprus;France;Greece;Italy;Japan;Malaysia;Portugal;South Korea;Sweden;Taiwan;United States
   Pharmaceuticals, Inc. Alnylam
      2026   Phase 3   JPRN-jRCT2031250851   Argentina;Australia;Austria;Belgium;Brazil;Canada;Cyprus;Denmark;France;Germany;Greece;Ireland;Italy;Japan;Malaysia;Mexico;Portugal;South Korea;Spain;Sweden;Switzerland;Taiwan;The Czech Republic;The Netherlands;The United Kingdom;The United States;Turkey
NXC-201 CAR-T
   Nexcella Inc.
      2024   Phase 1/Phase 2   NCT06097832   United States
Onpattro
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Oral drops solution
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Paracetamol
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
Paracetamolo
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Patisiran
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals
      2019   Phase 3   NCT03759379   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Italy;Japan;Malaysia;Mexico;Netherlands;Portugal;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224769   Asia except Japan;Europe;Japan;North America;Oceania;South America
Pegylated recombinant human hyaluronidase PH20
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
Peripheral blood stem cell transplantation
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
PF-06291826-00
   PFIZER INC
      2016   Phase 3   EUCTR2016-000868-42-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Pfizer Inc.
      2017   Phase 3   EUCTR2016-000868-42-NL   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-DE   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
PF-06291826-83
   PFIZER INC
      2016   Phase 3   EUCTR2016-000868-42-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Pfizer Inc.
      2017   Phase 3   EUCTR2016-000868-42-SE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-NL   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-DE   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-BE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000868-42-ES   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000868-42-CZ   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
PF-06291826-83, FX-1006A
   FoldRx Pharmaceuticals, a Pfizer Company
      2014   Phase 3   EUCTR2012-002465-35-SE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-NL   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-IT   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-GB   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-ES   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-DE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-BE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
PF-06291826-83/FX-1006A
   Pfizer Inc.
      2009   Phase 3   EUCTR2009-011535-12-SE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Pharmacological study
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
   National Cancer Institute (NCI)
      2009   Phase 1   NCT00890747   United States
      2001   Phase 1   NCT00030381   United States
      2001   Phase 1   NCT00025415   United States
Polymerase chain reaction
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Pomalidomide
   Barbara Ann Karmanos Cancer Institute
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
   Boston Medical Center
      2012   Phase 1/Phase 2   NCT01570387   United States
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2021   Phase 2   EUCTR2019-001962-13-IT   Italy
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
   Jin Lu, MD
      2024   Phase 2   NCT06342466   China
   M.D. Anderson Cancer Center
      2014   Phase 1   NCT01807286   United States
   OSPEDALE POLICLINICO S. MATTEO
      2012   -   EUCTR2011-001787-22-IT   Italy
   Weill Medical College of Cornell University
      2021   Phase 2   NCT04270175   United States
   Yongyong MA
      2024   -   NCT06455748   China
Pomalidomide 4 MG
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
Pomalidomide and dexamethasone
   IRCCS Policlinico S. Matteo
      2012   Phase 2   NCT01510613   Italy
Positron emission tomography
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Prednisone
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
Propylene glycol-free melphalan hydrochloride
   Boston Medical Center
      2018   Phase 2   NCT02994784   United States
Protein expression analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Psyllium
   Centre Hospitalier Universitaire de Nice
      2023   -   NCT04695340   France
Pyrrolidine
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Pyrrolidone
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Quality-OF-life assessment
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
Questionnaire administration
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
Questionnaires
   M.D. Anderson Cancer Center
      2014   Phase 1   NCT01807286   United States
Ranidil - 50 MG/5 ML soluzione iniettabile PER USO endovenoso 10 fiale
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Ranitidina
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Recombinant interferon alfa
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Southwest Oncology Group
      1996   Phase 2   NCT00002849   United States
Revlimid
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
Revusiran
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-005333-49-GB   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-SE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-DE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-BE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-003835-20-GB   Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
RNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Sacubitril / valsartan
   Puerta de Hierro University Hospital
      2025   Phase 3   NCT06712030   Spain
SAR445514
   Sanofi
      2023   Phase 1   NCT05839626   Australia;Belgium;Czechia;Hungary;Italy;Spain;United Kingdom
SAR650984
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Sarclisa
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Sargramostim
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Selinexor
   Weill Medical College of Cornell University
      2021   Early Phase 1   NCT04984330   United States
Siltuximab
   Memorial Sloan Kettering Cancer Center
      2017   Phase 2   NCT03315026   United States
Soldesam - 4 MG/ML soluzione iniettabile 3 fiale 1 ML
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
SOM0226
   SOM Biotech SL
      2014   Phase 1/Phase 2   NCT02191826   Spain
   SOM Innovation Biotech SL (SOM Biotech)
      2014   -   EUCTR2014-001586-27-ES   Spain
Sonrotoclax
   Peking University People's Hospital
      2026   Phase 2   NCT07335887   -
Standard OF care chemotherapy
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Prothena Biosciences Ltd.
      2021   Phase 3   NCT04973137   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;South Korea;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Standard OF care therapy
   Fondazione IRCCS Policlinico San Matteo di Pavia
      2019   Phase 2/Phase 3   NCT03474458   Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom
Stem cell collection
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
Stem cell infusion
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
      2008   Phase 2   NCT00790647   United States
      2001   Phase 2   NCT00075608   United States
Stem cell isolation
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
STI-6129
   Sorrento Therapeutics, Inc.
      2023   Phase 1   NCT05692908   -
      2021   Phase 1/Phase 2   NCT04316442   United States
Sunitinib malate
   National Cancer Institute (NCI)
      2009   Phase 1   NCT00890747   United States
Survey administration
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Tachipirina
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States
Tachipirina - 500 MG compresse10 compresse
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Tafamidis
   Fujimoto Naoki
      2020   Phase 4   JPRN-jRCT1041200007   -
   Kitai Takeshi
      2026   -   JPRN-jRCT1051250227   -
   Pfizer
      2026   -   NCT07494656   Germany
      2024   -   NCT06393465   United States
      2024   -   NCT06086353   India
      2023   -   NCT05139680   United States
      2022   -   NCT05560555   Spain
      2021   Phase 4   NCT04814186   China
      2021   -   NCT04801329   South Korea
      2016   Phase 3   NCT02791230   Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2011   Phase 3   NCT01435655   Japan
      2009   Phase 3   NCT00935012   United States
Tafamidis 61 milligrams
   Pfizer
      2024   -   NCT06321523   South Korea
Tafamidis meglumine
   PFIZER INC
      2016   Phase 3   EUCTR2016-000868-42-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Pfizer Inc.
      2017   Phase 3   EUCTR2016-000868-42-SE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-NL   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-DE   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-BE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000868-42-ES   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000868-42-CZ   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2009   -   EUCTR2009-011535-12-PT   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
      2009   -   EUCTR2009-011535-12-DE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
   Pfizer Japan Inc.
      2011   Phase 3   JPRN-jRCT2080221636   -
Tafamidis meglumine 20 MG soft gelatin capsules
   Pfizer Inc.
      2009   Phase 3   EUCTR2009-011535-12-SE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Tafamidis meglumine 20MG soft gelatin capsules
   FoldRx Pharmaceuticals, a Pfizer Company
      2014   Phase 3   EUCTR2012-002465-35-SE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-NL   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-IT   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-GB   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-ES   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-DE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-BE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
Talquetamab
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Targeted bcma autologous cart cell injection
   Beijing Boren Hospital
      2024   Early Phase 1   NCT07626476   China
Tasmar
   SOM Innovation Biotech SL (SOM Biotech)
      2014   -   EUCTR2014-001586-27-ES   Spain
Tauroursodeoxycholic acid and doxycycline
   Brigham and Women's Hospital
      2013   Phase 1/Phase 2   NCT01855360   United States
Teclistamab
   European Myeloma Network B.V.
      2025   Phase 2   NCT06649695   Australia;France;Germany;Greece;Italy;Netherlands
   Peking Union Medical College Hospital
      2025   Phase 2   NCT07079423   China
      2025   Phase 2   NCT06935162   China
   Peking University People's Hospital
      2025   -   NCT06699394   China
   Shanghai Zhongshan Hospital
      2026   Phase 2   NCT07638683   China
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
   Suzanne Lentzsch, MD
      2025   Phase 2   NCT07110844   United States
Thalidomide
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   Guangdong Provincial People's Hospital
      2020   Phase 4   NCT04612582   China
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
   University College, London
      2015   Phase 1/Phase 2   NCT02545907   United Kingdom
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Thiotepa
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
Tolcapone
   SOM Innovation Biotech SL (SOM Biotech)
      2014   -   EUCTR2014-001586-27-ES   Spain
Total-body irradiation
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
Transabdominal ultrasound
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Treatment FOR TTR amyloidosis
   Pfizer
      2019   -   NCT04108091   Japan
Treatment OF transthyretin (attr) amyloidosis IN observational study setting
   AstraZeneca
      2024   -   NCT06465810   Canada;China;Germany;Japan;Spain;United Kingdom;United States
Valganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Velcade
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022395-31-SE   Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
      2012   Phase 2   EUCTR2010-021445-42-BE   Belgium;Germany;Netherlands
      2011   Phase 2   EUCTR2010-021445-42-NL   Belgium;Germany;Netherlands
   University College London
      2010   -   EUCTR2009-014906-33-GB   United Kingdom
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Velcade*1FL 3,5MG
   JANSSEN-CILAG
      2005   -   EUCTR2004-004871-12-IT   Italy
Venetoclax
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
   Jin Lu, MD
      2024   -   NCT06192979   China
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   Tufts Medical Center
      2017   Phase 1   NCT03000660   United States
Venetoclax MTD with dexamethasone
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Venetoclax oral tablet, 200 MG
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Venetoclax oral tablet, 400 MG
   Columbia University
      2022   Phase 1/Phase 2   NCT05451771   United States
Vitamina A
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-001427-40-IT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
Vutrisiran
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals
      2025   Phase 3   NCT07223203   Australia;Brazil;Cyprus;France;Greece;Italy;Japan;Malaysia;Portugal;South Korea;Sweden;Taiwan;United States
      2019   Phase 3   NCT03759379   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Italy;Japan;Malaysia;Mexico;Netherlands;Portugal;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224769   Asia except Japan;Europe;Japan;North America;Oceania;South America
   Kitai Takeshi
      2026   -   JPRN-jRCT1051250227   -
   Pharmaceuticals, Inc. Alnylam
      2026   Phase 3   JPRN-jRCT2031250851   Argentina;Australia;Austria;Belgium;Brazil;Canada;Cyprus;Denmark;France;Germany;Greece;Ireland;Italy;Japan;Malaysia;Mexico;Portugal;South Korea;Spain;Sweden;Switzerland;Taiwan;The Czech Republic;The Netherlands;The United Kingdom;The United States;Turkey
Vyndaqel
   Pfizer
      2014   -   NCT02146378   -
Vyndaqel - 20 MG - capsula molle - USO orale - blister (PVC/ALU) 30 capsule
   PFIZER INC
      2016   Phase 3   EUCTR2016-000868-42-IT   Belgium;Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
Vyndaqel 20 MG soft capsule
   FoldRx Pharmaceuticals, a Pfizer Company
      2014   Phase 3   EUCTR2012-002465-35-SE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-NL   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-IT   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-GB   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-ES   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-DE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2012-002465-35-BE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
   Pfizer Inc.
      2017   Phase 3   EUCTR2016-000868-42-SE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-NL   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Italy;Japan;Netherlands;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-DE   Belgium;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-000868-42-BE   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000868-42-ES   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000868-42-CZ   Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States
Vyndaqel 20MG soft capsule
   Pfizer Inc.
      2009   Phase 3   EUCTR2009-011535-12-SE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
X-RAY imaging
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
YOLT-201
   YolTech Therapeutics Co., Ltd
      2024   Phase 1/Phase 2   NCT06539208   China
Yttrium-90 radiolabelled ANTI-CD66 antibody
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Yttrium90 radiolabelled antiCD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Zirtec
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
ZN-D5
   K-Group Alpha, Inc
      2023   Phase 1;Phase 2   EUCTR2021-003008-42-CY   Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;United Kingdom;United States
   K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
      2021   Phase 1/Phase 2   NCT05199337   Australia;Cyprus;Greece;Israel;Italy;Spain;United States
      2021   Phase 1;Phase 2   EUCTR2021-003008-42-GR   Australia;Cyprus;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;United States
   Zentalis Pharmaceuticals
      2022   Phase 1;Phase 2   EUCTR2021-003008-42-IT   Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States
Zyrtec
   NOVO NORDISK. S.P.A.
      2022   Phase 2   EUCTR2021-006226-49-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Portugal;Spain;United Kingdom;United States